Singapore Biotechnology Company Plans for IPO &Listing on ASX

July 14, 2015 - PRLog -- Sydney, Australia, 15 July 2015 – On Q Group Limited, changing its name to StemCell United Limited (“SCU” or “the Company”) (ACN 009104330), a Singapore-based biotechnology company headquartered in Australia, has issued a prospectus for a  Public Offering (“PO”) and listing on the Australian Securities Exchange (“ASX”) with the Australian Securities and Investment Commission (“ASIC”).  The PO opens yesterday on 14 July 2015.

The Company is announcing a public offer of 23,000,000 New Shares at the Offer Price of $0.20 per New Share (the “Offer”). The New Shares to be issued will represent approximately 6% of the Shares on issue on completion of the Offer and the entire transaction.

Following completion of the PO, SCU will acquire the Singapore based company StemCell United Pte Ltd (“SUP”). SUP is a biotechnology company which focuses on the extraction, culture, reproduction, and growth of plant stem cells for medicinal health and beauty applications in Traditional Chinese Medicine (“TCM”). TCM is a system of healthcare that includes herbal medicines with a history of development in China and other parts of East Asia dating back thousands of years. The underlying principles of TCM are very different from traditional western notions about health and illness.  Whether or not TCM is believed, studies have shown that Chinese herbal medicine can be successful in treating a range of disorders.

The Company aims to be the leading plant stemcell researcher, developer and producer offering a range of TCM products to preserve the health and youth of human beings based on its proprietary technology platform. Their proprietary technology takes 3 months to complete entire growth and process, resulting in faster to market the products and rapid turnover as compared to the traditional method which takes 3-5 years to grow and complete the process.

SUP currently sources, produces, markets and sells Daemonorops Draco Blume extract commonly known as Dragon’s Blood Resin (“Resina” or “血竭”), to TCM distributors and TCM manufacturing companies in Hong Kong and China. The Company intends also to produce and distribute Dendrobium Officinale Kimura et Migo (“Dendrobium” or “铁皮石斛”).

Business Outlook

Investing in the Company provides an opportunity to participate in a business that aims to supply high value product into the large TCM market in China.

SUP/SCU’s CEO Mr Gu commented: “An ASX listing will allow SCU to do more research and produce a range of TCM products based on our proprietary technology. Our aim is to continue to scale up the business through increasing the penetration of international markets and expansion of our product offering, while consolidating our market position in China. The ASX listing will help facilitate this by strengthening our balance sheet and increasing our visibility.”

Future Plans

By utilizing their proprietary technology to produce Denbrobium extract, they are capable to make a different formulation for traditional market and new market segments such as beauty care especially in Anti-aging, hair growth, wellness care and F&B products which will make SCU a pioneer in these markets.